Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 5/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | PAK4 | O96013 | 2/20 | 0.35 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834120 | 0.84 | PIK3CA (0.41) | HRH4NUDT1PIK3CAMTORPDE10A | |
| SCHEMBL30834096 | 0.80 | HRH4 (0.57) | HRH4PIK3CAPIK3R1JAK3PDE10A | |
| SCHEMBL30834084 | 0.80 | HRH4 (0.57) | HRH4PIK3CAPIK3R1JAK3PDE10A | |
| SCHEMBL30834101 | 0.80 | CYP1A2 (0.36) | HRH4NUDT1PIK3CAPDE10AADORA2A | |
| SCHEMBL4738959 | 0.77 | HRH4 (0.55) | HRH4PIK3CAPIK3R1JAK3ADORA2A | |
| SCHEMBL30834128 | 0.75 | HRH4 (0.40) | HRH4PIK3CAPDE10AADORA2AADORA1 | |
| SCHEMBL27201332 | 0.73 | PIK3CA (0.38) | PIK3CAPIK3R1MTOR | |
| SCHEMBL4735212 | 0.71 | HRH4 (0.48) | HRH4PIK3CAPIK3R1JAK3MTOR | |
| SCHEMBL4735201 | 0.71 | HRH4 (0.48) | HRH4PIK3CAPIK3R1JAK3MTOR | |
| SCHEMBL30834094 | 0.71 | NUDT1 (0.51) | HRH4NUDT1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | claimed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | claimed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | HRH4 4074/4885NUDT1 3459/4885PIK3CA 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.